Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease.

ABSTRACT:

Background

Renal secondary hyperparathyroidism (RHPT) is an inevitable consequence of chronic kidney disease (CKD). Paricalcitol might safely attenuate RHPT and proteinuria.

Hypothesis/objective

Paricalcitol decreases parathyroid hormone (PTH) and proteinuria in dogs with CKD.

Animals

Thirteen dogs with naturally acquired CKD.

Methods

Placebo-controlled clinical trial. Dogs were randomly allocated to receive a placebo or paricalcitol (14 ng/kg/day) in a crossover design of 2, 12-week arms. Dogs were evaluated every 3 weeks. Associations between treatment, visit, and the outcome variables were assessed using generalized estimating equations.

Results

PTH decreased by 22% (95% CI, 7%-35%, p = 0.006) in the paricalcitol-treated dogs and increased by 18% (95%

SUBMITTER: Chen H 

PROVIDER: S-EPMC11923454 | biostudies-literature | 2025 Mar-Apr

REPOSITORIES: biostudies-literature